CA2669991A1 — Imidazotriazines and imidazopyrimidines as kinase inhibitors
Assigned to Incyte Holdings Corp · Expires 2008-05-29 · 18y expired
What this patent protects
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and i midazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of canc er and other diseases related to the dysregulation of…
USPTO Abstract
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and i midazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of canc er and other diseases related to the dysregulation of kinase pathways.</SDOA B>
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.